4.7 Article

Circulating p-Cresyl Sulfate, Non-Hepatic Alkaline Phosphatase and Risk of Bone Fracture Events in Chronic Kidney Disease-Mineral Bone Disease

期刊

TOXINS
卷 13, 期 7, 页码 -

出版社

MDPI
DOI: 10.3390/toxins13070479

关键词

p-cresyl sulfate; alkaline phosphatase; bone fracture; chronic kidney disease-mineral and bone disorder

资金

  1. Ministry of Science and Technology [ECKH_W10808, MOST 109-2628-B-385 -001, 109-2221-E-038 -013]
  2. National Taiwan University Hospital [NTUH-110-S5154]
  3. Academia and Industry Collaboration Project of Taipei Medical University
  4. Renal Care Joint Foundation
  5. En Chu Kong Hospital
  6. Pharmofoods Medical Editing Co., Ltd. [A-108-031]

向作者/读者索取更多资源

This study investigated the association between PCS, NHALP, and bone fracture risk in hemodialysis patients, finding that elevated levels of PCS and NHALP were intricately linked to an increased risk of bone fractures. A joint evaluation of both markers was deemed more comprehensive than assessing each independently in predicting skeletal events.
Patients with chronic kidney disease (CKD), especially those undergoing hemodialysis, are at a considerably high risk of bone fracture events. Experimental data indicate that uremic toxins intricately involved in bone-related proteins exert multi-faced toxicity on bone cells and tissues, leading to chronic kidney disease-mineral and bone disorder (CKD-MBD). Nonetheless, information regarding the association between p-cresyl sulfate (PCS), non-hepatic alkaline phosphatase (NHALP) and skeletal events remains elusive. We aim to explore the association between PCS, NHALP and risk of bone fracture (BF) in patients with hemodialysis. Plasma concentrations of PCS and NHALP were ascertained at study entry. Cox proportional hazard regression analyses were used to determine unadjusted and adjusted hazard ratios (aHRs) of PCS for BF risk. In multivariable analysis, NHALP was associated with incremental risks of BFs [aHR: 1.06 (95% CI: 1.01-1.11)]. The association between the highest PCS tertile and BF risk remained robust [aHR: 2.87 (95% CI: 1.02-8.09)]. With respect to BF events, the interaction between NHALP and PCS was statistically significant (p value for the interaction term < 0.05). In addition to mineral dysregulation and hyperparathyroidism in hemodialysis patients, higher circulating levels of PCS and NHALP are intricately associated with incremental risk of BF events, indicating that a joint evaluation is more comprehensive than single marker. In light of the extremely high prevalence of CKD-MBD in the hemodialysis population, PCS may act as a pro-osteoporotic toxin and serve as a potential surrogate marker for skeletal events.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据